BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Johnson & Johnson (JNJ) Exec Says Hip Implant Was Recalled for Clinical Reasons


3/14/2013 7:42:24 AM

Andrew Ekdahl, president of Johnson & Johnson (JNJ)’s DePuy orthopedic products unit, told a Chicago jury that the company recalled 93,000 hip implants in August 2010 because they weren’t meeting “clinical expectations.” Ekdahl’s testimony came on the third day of a state court trial in which Carol Strum, 54, claims her ASR XL hip was defective. Strum, an Illinois nurse, had the all-metal device implanted in 2008, and she had it replaced three years later in a so-called revision surgery. Strum’s lawsuit is the second of 10,750 over the ASR hips to go to trial. “The revision rate was not acceptable,” Ekdahl testified. That was the reason for the recall, he said. J&J recalled the ASR after saying 13 percent failed within five years in the U.K., requiring revisions. Ekdahl was asked about a DePuy document signed by top company officials days before the recall. The document, from the Health Hazard/Risk Evaluation Review Board, listed three possible explanations for the recall. DePuy checked Class A for “defective product that would affect product performance and/or could cause health problems.” In his opening statement on March 13, J&J attorney Richard Sarver said the device was not defective. ‘Many Factors:’ “Many factors contribute to the overall revision rate so a single root cause cannot be defined at this time,” Sarver said. “We absolutely didn’t say the product is a defective product. We said, ‘We don’t know. We need to figure this out.’” To say the recall “is an admission of a defect, it is absolutely absurd,” according to Sarver.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES